Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis.

Mikecz K, Glant TT, Markovics A, Rosenthal KS, Kurko J, Carambula RE, Cress S, Steiner HL Rd, Zimmerman DH.

Vaccine. 2017 Jul 13;35(32):4048-4056. doi: 10.1016/j.vaccine.2017.05.009. Epub 2017 Jun 3.

2.

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.

Rosenthal KS, Stone S, Koski G, Zimmerman DH.

J Immunol Res. 2017;2017:3613505. doi: 10.1155/2017/3613505. Epub 2017 Mar 26.

3.

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Rosenthal KS, Mikecz K, Steiner HL 3rd, Glant TT, Finnegan A, Carambula RE, Zimmerman DH.

Expert Rev Vaccines. 2015 Jun;14(6):891-908. doi: 10.1586/14760584.2015.1026330. Epub 2015 Mar 18. Review.

4.

LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.

Zimmerman DH, Steiner H 3rd, Carmabula R, Talor E, Rosenthal KS.

J Vaccines Vaccin. 2012 Sep 20;3(5). pii: 149.

5.

J-LEAPS peptide and LEAPS dendritic cell vaccines.

Rosenthal KS, Taylor P, Zimmerman DH.

Microb Biotechnol. 2012 Mar;5(2):203-13. doi: 10.1111/j.1751-7915.2011.00278.x. Epub 2011 Sep 6. Review.

6.

J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.

Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS.

Vaccine. 2010 Aug 2;28(34):5533-42. doi: 10.1016/j.vaccine.2010.06.043. Epub 2010 Jun 25.

PMID:
20600501
7.

Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens.

Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS.

Cell Immunol. 2010;262(1):1-5. doi: 10.1016/j.cellimm.2010.01.003. Epub 2010 Feb 1.

8.

CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model.

Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, O'Neill SP, Talor E, Rosenthal KS.

Int Immunopharmacol. 2010 Apr;10(4):412-21. doi: 10.1016/j.intimp.2009.12.016. Epub 2010 Jan 13.

PMID:
20074669
9.

L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.

Cihakova D, Barin JG, Baldeviano GC, Kimura M, Talor MV, Zimmerman DH, Talor E, Rose NR.

Int Immunopharmacol. 2008 May;8(5):624-33. doi: 10.1016/j.intimp.2008.01.004. Epub 2008 Jan 29.

10.

Vaccines: all things considered.

Rosenthal KS, Zimmerman DH.

Clin Vaccine Immunol. 2006 Aug;13(8):821-9. Review. No abstract available.

11.

Ligand epitope antigen presentation system vaccines against herpes simplex virus.

Goel N, Zimmerman DH, Rosenthal KS.

Front Biosci. 2005 Jan 1;10:966-74. Print 2005 Jan 1. Review.

PMID:
15569635
12.

The L.E.A.P.S. approach to vaccine development.

Zimmerman DH, Rosenthal KS.

Front Biosci. 2005 Jan 1;10:790-8. Print 2005 Jan 1. Review.

PMID:
15569618
13.

A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner.

Charoenvit Y, Brice GT, Bacon D, Majam V, Williams J, Abot E, Ganeshan H, Sedegah M, Doolan DL, Carucci DJ, Zimmerman DH.

Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63.

14.

CEL-1000--a peptide with adjuvant activity for Th1 immune responses.

Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH.

Vaccine. 2004 Jun 23;22(19):2368-73.

PMID:
15193396
15.

A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease.

Goel N, Docherty JJ, Fu MM, Zimmerman DH, Rosenthal KS.

J Virol Methods. 2002 Dec;106(2):153-8.

PMID:
12393145
16.
17.

Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.

Pisarev VM, Parajuli P, Mosley RL, Sublet J, Kelsey L, Sarin PS, Zimmerman DH, Winship MD, Talmadge JE.

Int J Immunopharmacol. 2000 Nov;22(11):865-76.

PMID:
11090695
18.

Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.

Zimmerman DH, Ulrich JT, Wright C, Lloyd JP, Winship MD, Sarin PS.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):741-9.

PMID:
9643374
19.

Collect, but keep the space.

Zimmerman DH.

Patient Acc. 1986 Jul;9(7):2-3. No abstract available.

PMID:
10278728
20.

AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations.

Ragni MV, Tegtmeier GE, Levy JA, Kaminsky LS, Lewis JH, Spero JA, Bontempo FA, Handwerk-Leber C, Bayer WL, Zimmerman DH, et al.

Blood. 1986 Mar;67(3):592-5.

21.

Lack of oral HSV-2 in a college student population.

Docherty JJ, Trimble JJ, Roman SR, Faulkner SC, Naugle FP, Mundon FK, Zimmerman DH.

J Med Virol. 1985 Jul;16(3):283-7.

PMID:
2993498
23.

Incidence of herpes simplex virus types 1 and 2 in penile lesions of college men.

Docherty JJ, Lohse MA, Dellaria MF, Naugle FP, Mason CW, Knerr RA, McDermott HM, Mundon FK, Zimmerman DH.

J Med Virol. 1984;13(2):163-70.

PMID:
6319589
24.

Rapid quantitation of serum immunoglobulins with a miniature centrifugal analyzer.

Koch TR, Adolf PK, Zimmerman DH, Knoblock EC, Leitz VM.

Clin Chem. 1982 Mar;28(3):502-4.

25.

125I-lipid A binding by individual macrophage cells: cell purification, culture, and autoradiographic analysis on a single surface.

Gregory SH, Zimmerman DH, Kern M.

Anal Biochem. 1980 Sep 1;107(1):246-50. No abstract available.

PMID:
7435953
26.
27.
28.

Comparison of sensitivity of radioimmunoassay and immune electron microscopy for detecting hepatitis A antigen in fecal extracts.

Hall WT, Bradley DW, Madden DL, Zimmerman DH, Brandt DE.

Proc Soc Exp Biol Med. 1977 Jun;155(2):193-8. No abstract available.

PMID:
866348
29.

Solid-phase enzyme immunoassay for hepatitis B surface antigen.

Wei R, Knight GJ, Zimmerman DH, Bond HE.

Clin Chem. 1977 May;23(5):813-5.

30.

A simple procedure for labeling the lipid A moiety of lipopolysaccharide with I.

Zimmerman DH, Kern M.

Anal Biochem. 1977 Feb;77(2):340-5. No abstract available.

PMID:
842824
32.
34.

Differentiation of lymphoid cells: the in vitro emergence of immunoglobulin M-secreting cells.

Zimmerman DH, Kern M.

J Immunol. 1973 Sep;111(3):761-9. No abstract available.

PMID:
4795259
35.
37.
38.

Effect of x-irradiation on rat thymocyte nuclei: I phosphate metabolism.

Zimmerman DH, Cromroy HL.

Life Sci. 1967 Mar 15;6(6):621-7. No abstract available.

PMID:
6034179
39.

Relationships of stress, tranquilizers, and serum cholesterol levels in a sample population under study for coronary heart disease.

Chapman JM, Reeder LG, Massey FJ Jr, Borun ER, Picken B, Browning GG, Coulson AH, Zimmerman DH.

Am J Epidemiol. 1966 May;83(3):537-47. No abstract available.

PMID:
5932700
40.

A PUBLIC RELATIONS COURSE FOR BUSINESS OFFICE EMPLOYEES.

ZIMMERMAN DH.

Hospitals. 1964 Apr 16;38:53-4. No abstract available.

PMID:
14140964
41.

Improving nursing home administration: a report of an experiment in education.

REEDER LG, ZIMMERMAN DH, SHELDON EB.

J Health Hum Behav. 1963;4:29-36. No abstract available.

PMID:
13973572

Supplemental Content

Loading ...
Support Center